Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jinf.2025.106417 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Zidebactam restores cefiderocol sensitivity in resistant bacteria.
J Infect
January 2025
Department of Emergency Medicine, Second Affiliated Hospital, Department of Epidemiology and Biostatistics, School of Public Health, The Key Laboratory of Intelligent Preventive Medicine of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou 310058, China; Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China. Electronic address:
Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant .
Antimicrob Agents Chemother
March 2024
Antabio SAS, Labège, France.
Article Synopsis
- - ANT3310 is a new drug being tested alongside meropenem (MEM) to treat serious infections caused by drug-resistant bacteria, specifically carbapenem-resistant Gram-negative pathogens.
- - In tests with 905 clinical bacterial isolates, the combination of MEM and ANT3310 showed significantly better antibacterial activity, reducing MIC values for carbapenem-resistant Enterobacterales from over 32 µg/mL to much lower levels.
- - The combination of MEM and ANT3310 effectively inhibited the growth of nearly all tested resistant strains and proved effective in mouse models of thigh and lung infections, showing promise as a treatment option compared to other existing drug combinations.
Zidebactam restores sulbactam susceptibility against carbapenem-resistant isolates.
Front Cell Infect Microbiol
July 2022
Center for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA, United States.
Carbapenems are commonly used to treat infections caused by multidrug-resistant (MDR) bacteria. Unfortunately, carbapenem resistance is increasingly reported in many gram-negative bacteria, especially . Diazabicyclooctane (DBO) β-lactamase inhibitors, such as avibactam (AVI), when combined with sulbactam successfully restore sulbactam susceptibility against certain carbapenem-resistant (CRAB) isolates.
View Article and Find Full Text PDFIn vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.
J Antimicrob Chemother
June 2022
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.
Objectives: Ertapenem has proven to be an effective antimicrobial; however, increasing enzyme-mediated resistance has been noted. Combination with zidebactam, a β-lactam enhancer, is restorative. Human-simulated regimens (HSRs) of ertapenem and zidebactam alone and in combination (WCK 6777; 2 g/2 g q24h) were assessed for efficacy against carbapenemase-producing Klebsiella pneumoniae (CP-KP) in the pneumonia model.
View Article and Find Full Text PDFAntimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections.
Antibiotics (Basel)
November 2021
Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.
Metallo-β-lactamases (MBLs) are among the most challenging bacterial enzymes to overcome. Aztreonam (ATM) is the only β-lactam not hydrolyzed by MBLs but is often inactivated by co-produced extended-spectrum β-lactamases (ESBL). We assessed the activity of the combination of ATM with old and new β-lactamases inhibitors (BLIs) against MBL and ESBL co-producing Gram-negative clinical isolates.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!